Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic
Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic Supplementation in Hemodialysis Patients
- Symbiotic
- Uremic Toxins
- Gut -Microbiota
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- Tungs' Taichung Metroharbour Hospital
- Enrolment target
- 30
- Started
- 4 May 2026
- Main results due
- 31 December 2026
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Adults aged 18 years or older receiving maintenance hemodialysis patients for at least 3 months Exclusion Criteria: 1. Use of probiotic supplements within the last month; 2. Hospitalization within the past month for acute infections or CKD-related complications; 3. History of major intestinal surgeries (gastrectomy, cholecystectomy; appendectomy allowed); 4. Presence of viral hepatitis, liver cirrhosis, active malignancy, advanced congestive heart failure, or thyroid disorders; 5. Use of antibiotics or immunosuppressive therapy within the preceding three months.
What this study is about
In the sponsor’s own words, from the registry.
Patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis frequently exhibit significant gut microbiota dysbiosis and increased intestinal permeability. These alterations enable the translocation of endotoxins and gut-derived uremic toxins-such as indoxyl sulfate and p-cresyl sulfate-into the systemic circulation, exacerbating systemic inflammation, elevating cardiovascular risk, and accelerating disease progression.
Multispecies synbiotic supplementation has emerged as a promising intervention to restore gut microbial equilibrium, strengthen intestinal barrier function, and reduce the systemic load of harmful microbial metabolites. Through modulation of inflammatory pathways and reduction of circulating uremic toxins, synbiotic hold potential to improve clinical outcomes in this vulnerable population.
Although preclinical and some clinical evidence suggests benefits of probiotic therapy, comprehensive clinical trials specifically examining multispecies synbiotic effects on gut inflammatory markers, gut derived metabolite profiles, and uremic toxin levels in hemodialysis patients remain limited. This pilot study aims to address this gap by investigating the biological and clinical effects of a 12-week multispecies regimen in adult maintenance hemodialysis patients.
Study sites(1)
Tungs' Taichung Metroharbour Hospital
Taichung, Wuqi District, Taiwan
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07443280. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me